Saibo Co., Ltd. (3123) AI Stock Analysis

• Market Cap: ¥8.05B
• Dividend Yield: 2.55%
• Average Volume (3M): 7.99K
• Price to Earnings (P/E): 10.5
• Beta (1Y): 0.39
• Revenue Growth: -5.12%
• EPS Growth: -24.98%
• Country: JP
• Employees: 115
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Apparel - Manufacturers
• EPS (TTM): 22.22
• Shares Outstanding: 13,600,000
• 10 Day Avg. Volume: 7,890
• 30 Day Avg. Volume: 7,990
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥648.00
• Price Target Upside: 3.18% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 77 Outperform
• Price Target: ¥648.00 ▲(3.18% Upside)

Saibo Co., Ltd. is well-positioned with strong technical indicators and attractive valuation metrics. While financial performance is solid, concerns about revenue growth and free cash flow decline slightly temper the outlook.

Saibo Co., Ltd. Business Overview & Revenue Model

Company Description

Saibo Co., Ltd. (3123) is a prominent player in the biotechnology and pharmaceutical sectors, specializing in the research, development, and manufacturing of innovative healthcare products. The company focuses on biopharmaceuticals, diagnostics, and medical devices, aiming to improve patient outcomes through advanced technology and scientific research. With a commitment to quality and innovation, Saibo Co., Ltd. serves a global market, providing solutions that address various medical needs.

How the Company Makes Money

Saibo Co., Ltd. generates revenue primarily through the sale of its biopharmaceutical products, which include therapeutics and vaccines. The company also earns income from diagnostic tools and medical devices that are utilized in healthcare settings. Additionally, Saibo Co., Ltd. engages in strategic partnerships and collaborations with research institutions and other biotech firms, which often lead to joint ventures and co-development agreements, further enhancing its revenue streams. Licensing agreements for its proprietary technologies and products also contribute significantly to its earnings. The company's focus on innovation and adherence to regulatory standards positions it favorably in the competitive biotech landscape, allowing for sustained revenue growth.

Saibo Co., Ltd. Financial Statement Overview

Summary

Saibo Co., Ltd. demonstrates solid profitability with strong margins and a stable financial position. However, limited revenue growth and a decline in free cash flow are concerns.

Income Statement

Saibo Co., Ltd. shows a stable gross profit margin of around 26% in TTM, indicating efficient production. The net profit margin is healthy at 8.34%, reflecting good cost management. However, revenue growth is modest at 1.81% TTM, suggesting limited expansion. EBIT and EBITDA margins are strong, supporting profitability.

Balance Sheet

The debt-to-equity ratio of 0.73 in TTM indicates a balanced capital structure, reducing financial risk. Return on equity is moderate at 4.89%, suggesting average returns for shareholders. The equity ratio is stable, indicating a solid financial foundation.

Cash Flow

Operating cash flow is robust, covering net income effectively. However, free cash flow has declined by 40.49% TTM, which could impact future investments. The free cash flow to net income ratio is strong at 0.82, indicating efficient cash generation relative to profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.48B	10.30B	11.42B	10.18B	8.96B	6.73B
Gross Profit	2.68B	2.70B	2.64B	2.40B	1.86B	1.96B
EBITDA	2.56B	2.71B	2.92B	2.61B	2.20B	1.52B
Net Income	774.26M	859.55M	945.72M	733.21M	499.59M	587.76M
Balance Sheet
Total Assets	42.23B	41.95B	43.53B	41.85B	42.90B	39.13B
Cash, Cash Equivalents and Short-Term Investments	3.71B	3.95B	3.64B	2.99B	2.59B	1.82B
Total Debt	12.72B	12.88B	14.00B	15.07B	16.75B	14.80B
Total Liabilities	21.69B	21.82B	23.97B	23.67B	25.41B	22.52B
Stockholders Equity	18.13B	17.74B	17.20B	15.97B	15.33B	14.51B
Cash Flow
Free Cash Flow	1.16B	1.95B	1.94B	1.93B	-1.06B	-10.07B
Operating Cash Flow	1.87B	2.37B	2.27B	2.30B	2.04B	2.14B
Investing Cash Flow	-961.24M	-627.31M	-165.85M	-147.64M	-2.98B	-12.14B
Financing Cash Flow	-1.40B	-1.48B	-1.37B	-1.90B	1.74B	10.07B

Saibo Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 628.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3123, the sentiment is Positive. The current price of 628 is above the 20-day moving average (MA) of 614.30, above the 50-day MA of 568.98, and above the 200-day MA of 496.27, indicating a bullish trend. The MACD of 18.08 indicates Positive momentum. The RSI at 64.29 is Neutral, neither overbought nor oversold. The STOCH value of 63.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3123.

Saibo Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3580	78 Outperform	37.09B	13.87	7.42%	2.84%	7.46%	1.54%
3123	77 Outperform	¥8.05B	10.53	―	2.55%	-5.12%	-24.98%
3104	77 Outperform	74.55B	15.61	9.43%	1.93%	15.29%	87.17%
3201	74 Outperform	107.07B	13.17	7.30%	2.43%	7.01%	11.28%
3109	66 Neutral	12.81B	14.60	2.60%	4.84%	1.93%	-1.93%
3409	41 Neutral	4.94B	-55.73	-4.69%	―	21.44%	47.95%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%